01—Abstract
Summary
Summary of the 8-K filed November 19, 2024. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly (LLY) disclosed in an 8-K filed November 19, 2024 that its Board has elected Jon Moeller, Chairman, President and CEO of Procter & Gamble, as a new director effective December 1, 2024.
Moeller, who will sit on the Audit Committee and the Directors and Corporate Governance Committee, is deemed independent under NYSE standards and is not party to any related-party transaction under Item 404(a) of Regulation S-K. He will receive the standard non-employee director compensation and must stand for shareholder election at the May 2026 annual meeting. Karen Walker, a director since 2018 and a member of the Audit and Talent and Compensation Committees, will resign from the Board effective December 31, 2024.
The company states her departure did not result from any disagreement with management on operations, policies or practices. Starting in 2025, she is expected to collaborate with Lilly on digital commercial activities, a signal that the company is investing in its digital and commercial capabilities as it scales. For investors, the filing is a routine governance change with no financial figures, guidance, or material transactions disclosed.
The main points are the addition of an experienced consumer-goods executive with finance and strategy background to the Audit Committee, and the transition of a longtime director into an operating role. The filing does not indicate any change in Lilly's financial position or outlook.
02—Key points
Key Highlights
- Jon Moeller, Chairman, President and CEO of Procter & Gamble, joins Lilly's Board effective December 1, 2024.
- Moeller will serve on the Audit Committee and the Directors and Corporate Governance Committee, adding consumer-company finance and strategy experience to oversight functions.
- The Board determined Moeller is independent under NYSE standards and the company's director independence guidelines.
- Karen Walker, a director since 2018 and member of the Audit and Talent and Compensation Committees, resigns effective December 31, 2024.
- Walker's resignation was not due to any disagreement with the company on operations, policies or practices.
- Walker will collaborate with Lilly on digital commercial activities starting in 2025, supporting the company's digital and commercial scaling efforts.
- The filing contains no financial results, guidance, or material transactions; it is a board composition change only.
03—Questions
Frequently Asked Questions
Does this board change affect Lilly's financial outlook?
The filing contains no financial data, guidance, or forward-looking financial statements. It is a governance change and does not by itself indicate any change to Lilly's financial outlook.
Who is Jon Moeller and why is his appointment notable?
Jon Moeller is Chairman, President and CEO of Procter & Gamble and has been part of P&G's leadership for over two decades, including roles as vice chairman, CFO and COO. His finance and operational experience at a large consumer company may add perspective to Lilly's Audit Committee.
Why is Karen Walker leaving the board, and is it a concern?
Lilly says Walker's resignation did not arise from any disagreement with the company on operations, policies or practices. She will transition to a role collaborating on digital commercial activities in 2025, which suggests a continued relationship with the company rather than a departure from it.
Does Moeller have any conflicts or related-party relationships with Lilly?
The company states that Moeller is independent under NYSE and its own guidelines, has no arrangements with any person regarding his selection, and is not party to any transaction requiring disclosure under Item 404(a) of Regulation S-K.
When will shareholders vote on Moeller's board seat?
Moeller will stand for election by Lilly shareholders at the company's annual meeting in May 2026, consistent with the normal director election cycle.
04—Continue